Cargando…

(18)F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism

Patients with primary hyperparathyroidism (pHPT) can develop persistent (P-pHPT) or recurrent (R-pHPT) disease after parathyroidectomy. Before recommending reoperation, recurrence must be accurately identified because of the high risk of complications. Our study evaluates (18)F-fluorocholine ((18)F-...

Descripción completa

Detalles Bibliográficos
Autores principales: Latge, Adrien, Riehm, Sophie, Vix, Michel, Bani, Jacob, Ignat, Mihaela, Pretet, Valentin, Helali, Mehdi, Treglia, Giorgio, Imperiale, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700343/
https://www.ncbi.nlm.nih.gov/pubmed/34943620
http://dx.doi.org/10.3390/diagnostics11122384
_version_ 1784620734211948544
author Latge, Adrien
Riehm, Sophie
Vix, Michel
Bani, Jacob
Ignat, Mihaela
Pretet, Valentin
Helali, Mehdi
Treglia, Giorgio
Imperiale, Alessio
author_facet Latge, Adrien
Riehm, Sophie
Vix, Michel
Bani, Jacob
Ignat, Mihaela
Pretet, Valentin
Helali, Mehdi
Treglia, Giorgio
Imperiale, Alessio
author_sort Latge, Adrien
collection PubMed
description Patients with primary hyperparathyroidism (pHPT) can develop persistent (P-pHPT) or recurrent (R-pHPT) disease after parathyroidectomy. Before recommending reoperation, recurrence must be accurately identified because of the high risk of complications. Our study evaluates (18)F-fluorocholine ((18)F-FCH) PET/CT and 4D-CT integrated in PET/4D-CT in patients with P-pHPT/R-pHPT. Patients with P-pHPT/R-pHPT investigated by (18)F-FCH PET/4D-CT between May 2018 and March 2021 were retrospectively included. Forty-two patients were included, 37 of whom underwent 4D-CT. The sensitivity and detection rate (DR%) were 95% and 88% for (18)F-FCH PET/CT and 70% and 63% for 4D-CT, respectively. PET/CT and 4D-CT were concordant in 18/24 glands and concordant and positive in 15/24 (63%) glands. Discordant results were obtained for 6/24 glands. The surgical success rate was 65%. PET/CT showed significantly higher sensitivity than 4D-CT. Dynamic CT allowed the identification of no additional glands missed by PET/CT, and the combination of the 2 techniques did not improve the sensitivity or DR%. (18)F-FCH PET/CT appears to be a valuable technique to accurately detect hyperfunctioning parathyroid tissue in patients with P-pHPT/R-pHPT and is better than 4D-CT. Except for cases with doubtful locations of PET targets that may require 4D-CT for surgical guidance, standard nonenhanced (18)F-FCH PET/CT can be effectively recommended in patients with P-pHPT/R-pHPT before reoperation.
format Online
Article
Text
id pubmed-8700343
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87003432021-12-24 (18)F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism Latge, Adrien Riehm, Sophie Vix, Michel Bani, Jacob Ignat, Mihaela Pretet, Valentin Helali, Mehdi Treglia, Giorgio Imperiale, Alessio Diagnostics (Basel) Article Patients with primary hyperparathyroidism (pHPT) can develop persistent (P-pHPT) or recurrent (R-pHPT) disease after parathyroidectomy. Before recommending reoperation, recurrence must be accurately identified because of the high risk of complications. Our study evaluates (18)F-fluorocholine ((18)F-FCH) PET/CT and 4D-CT integrated in PET/4D-CT in patients with P-pHPT/R-pHPT. Patients with P-pHPT/R-pHPT investigated by (18)F-FCH PET/4D-CT between May 2018 and March 2021 were retrospectively included. Forty-two patients were included, 37 of whom underwent 4D-CT. The sensitivity and detection rate (DR%) were 95% and 88% for (18)F-FCH PET/CT and 70% and 63% for 4D-CT, respectively. PET/CT and 4D-CT were concordant in 18/24 glands and concordant and positive in 15/24 (63%) glands. Discordant results were obtained for 6/24 glands. The surgical success rate was 65%. PET/CT showed significantly higher sensitivity than 4D-CT. Dynamic CT allowed the identification of no additional glands missed by PET/CT, and the combination of the 2 techniques did not improve the sensitivity or DR%. (18)F-FCH PET/CT appears to be a valuable technique to accurately detect hyperfunctioning parathyroid tissue in patients with P-pHPT/R-pHPT and is better than 4D-CT. Except for cases with doubtful locations of PET targets that may require 4D-CT for surgical guidance, standard nonenhanced (18)F-FCH PET/CT can be effectively recommended in patients with P-pHPT/R-pHPT before reoperation. MDPI 2021-12-17 /pmc/articles/PMC8700343/ /pubmed/34943620 http://dx.doi.org/10.3390/diagnostics11122384 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Latge, Adrien
Riehm, Sophie
Vix, Michel
Bani, Jacob
Ignat, Mihaela
Pretet, Valentin
Helali, Mehdi
Treglia, Giorgio
Imperiale, Alessio
(18)F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism
title (18)F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism
title_full (18)F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism
title_fullStr (18)F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism
title_full_unstemmed (18)F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism
title_short (18)F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism
title_sort (18)f-fluorocholine pet and 4d-ct in patients with persistent and recurrent primary hyperparathyroidism
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700343/
https://www.ncbi.nlm.nih.gov/pubmed/34943620
http://dx.doi.org/10.3390/diagnostics11122384
work_keys_str_mv AT latgeadrien 18ffluorocholinepetand4dctinpatientswithpersistentandrecurrentprimaryhyperparathyroidism
AT riehmsophie 18ffluorocholinepetand4dctinpatientswithpersistentandrecurrentprimaryhyperparathyroidism
AT vixmichel 18ffluorocholinepetand4dctinpatientswithpersistentandrecurrentprimaryhyperparathyroidism
AT banijacob 18ffluorocholinepetand4dctinpatientswithpersistentandrecurrentprimaryhyperparathyroidism
AT ignatmihaela 18ffluorocholinepetand4dctinpatientswithpersistentandrecurrentprimaryhyperparathyroidism
AT pretetvalentin 18ffluorocholinepetand4dctinpatientswithpersistentandrecurrentprimaryhyperparathyroidism
AT helalimehdi 18ffluorocholinepetand4dctinpatientswithpersistentandrecurrentprimaryhyperparathyroidism
AT tregliagiorgio 18ffluorocholinepetand4dctinpatientswithpersistentandrecurrentprimaryhyperparathyroidism
AT imperialealessio 18ffluorocholinepetand4dctinpatientswithpersistentandrecurrentprimaryhyperparathyroidism